Videos

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Giuseppe Curigliano, MD, PhD, from…

14 Jun 2016

Highlights of the 10th European Cancer Conference (EBCC-10) by Dr Giuseppe Curigliano

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the…

14 Jun 2016

Themes of the 10th European Breast Cancer Conference (EBCC-10)

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf…

14 Jun 2016

Understanding the unique aspects of immunotherapy for lung cancer

At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover…

14 Jun 2016

Immunotherapy for head and neck cancer

At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover…

14 Jun 2016

Improving the treatment of advanced renal cell carcinoma

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf…

14 Jun 2016

Predictive biomarkers for immunotherapy in non-small cell lung cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm…

14 Jun 2016

Next-generation sequencing to guide treatment decision-making

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm…

14 Jun 2016

Introducing next-generation sequencing into the clinical care of cancer

Recent advances in the biological understanding of thyroid cancer have led to the development of targeted therapies, such as the tyrosine kinase…

14 Jun 2016

Early versus delayed use of tyrosine kinase inhibitors for thyroid cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany…

14 Jun 2016

Updating the treatment algorithm for metastatic melanoma

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany…

14 Jun 2016

Changing the treatment landscape of metastatic melanoma

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany…

14 Jun 2016

Clinical decision-making for pancreatic cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany…

14 Jun 2016

The significance of BRCA mutations in pancreatic cancer

Pancreatic cancer is a leading cause of cancer-related deaths in developed countries. At the German Cancer Congress 2016, held in Berlin, Germany, from…

14 Jun 2016

Treatment of pancreatic cancer: Overview of the continued progress

Hematology

13 Jun 2016

The DA-EPOCH-R clinical trial in Burkitt’s lymphoma

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA, gives an overview of the interim analysis of a multicenter prospective…

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…

25 May 2016

KEYNOTE-010: Pembrolizumab versus docetaxel in advanced PD-L1-positive NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…

25 May 2016

ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…

25 May 2016

Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS…

25 May 2016

Immunotherapy for hepatocellular carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD…

25 May 2016

Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…

25 May 2016

Endocrine therapy in pregnant women with breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Suresh Kumarasamy, MBBS…

25 May 2016

Olaparib and bevacizumab: On the horizon for treating ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…

25 May 2016

Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer

25 May 2016

From biologics to biosimilars

The efficacy and safety of canakinumab in active hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS) and the implications of the results for the future treatment of patients with the condition.

19 Apr 2016

Treating Active HIDS with Canakinumab

At the American College of Rheumatology Annual Meeting, topic of interest is the pathophysiology and treatment of the condition hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS)

19 Apr 2016

Pathophysiology and Treatment of HIDS

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen…

19 Apr 2016

Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen Lachmann…

19 Apr 2016

Treatment Strategies for TRAPS

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Jasmin Kuemmerle…

19 Apr 2016

Treatments for Patients with CAPS

Took place during the 11th Congress of ECCO.

12 Apr 2016

Discussion on mild and moderate IBD treatment led by Prof Geert D’Haens

Took place during the 11th Congress of ECCO. Dr Pieter Hindryckx, Department of Gastroenterology, University Hospital of Ghent, Ghent, Belgium considers…

12 Apr 2016

Success factors in the treatment of uncomplicated CD by Dr Pieter Hindryckx

Took place during the 11th Congress of ECCO. During this symposium Dr Ailsa Hart, Director, IBD Unit, St Mark’s Hospital, London, UK discusses the…

12 Apr 2016

Success factors in the treatment of mild-to-moderate UC by Dr Ailsa Hart

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS…

9 Mar 2016

Precision medicine for metastatic breast cancer

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a…

20 Feb 2016

Overview of a Phase I study of ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Atsushi Ohtsu, MD, PhD…

5 Feb 2016

Roles of targeted therapy and immunotherapy for gastrointestinal cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes…

5 Feb 2016

ESMO 2015 highlights: Putting ovarian cancer management into perspective

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD…

5 Feb 2016

Defining ESMO Clinical Practice Guidelines at ESMO Asia 2015

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste…

5 Feb 2016

Phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD…

5 Feb 2016

Update from CheckMate 057: Nivolumab versus docetaxel in advanced non-squamous NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from…

5 Feb 2016

Therapeutic advances in immune checkpoint inhibitors for head and neck cancers

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from…

5 Feb 2016

KEYNOTE-028: Phase 1b trial of pembrolizumab in PD-L1-positive nasopharyngeal carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from…

5 Feb 2016

LUX-H&N1: Phase 3 trial of afatinib versus methotrexate for head and neck squamous cell carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Fatima Cardoso, MD, from…

5 Feb 2016

ESMO Clinical Practice Guidelines: Breast cancer case presentation

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress…

5 Feb 2016

Balancing therapeutics and patient access to new cancer drugs

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Martin Reck, MD, PhD…

4 Feb 2016

Updates from CheckMate 017 and CheckMate 057: Nivolumab, anti-PD1, for non-small cell lung cancer

Recently, there have been numerous advances in the biological understanding of ovarian cancer. At the European Society for Medical Oncology (ESMO) Asia…

4 Feb 2016

Olaparib: An opportunity for personalised medicine in BRCA-related ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD…

4 Feb 2016

Optimising sequencing of new treatments for prostate cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann…

4 Feb 2016

A new definition of genetic counselling for ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…

4 Feb 2016

KEYNOTE-010: Pembrolizumab, anti-PD-1, for advanced NSCLC with PD-L1 expression

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD…

4 Feb 2016

Improving outcomes from advanced prostate cancer

Ola Landgren, MD, PhD from National Cancer Institute, Bethesda, MD talks about cardio-oncology in multiple myeloma (MM). In this new era of more…

4 Feb 2016

Cardio-oncology in multiple myeloma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…

4 Feb 2016

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…

4 Feb 2016

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…

4 Feb 2016

AZD9291, an EGFR-TKI, for T790M-mediated resistance in non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…

4 Feb 2016

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…

4 Feb 2016

Oncogene-addicted non-small cell lung cancer

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer…

4 Feb 2016

Quality of life and new therapeutic options for metastatic castration-resistant prostate cancer

An interview with Dr Ian Jackson (Consultant Anaesthetist, York Teaching Hospital NHS Foundation Trust) following the ‘GreenLight™ Laser System for Day…

3 Feb 2016

Potential Impact of New Techniques for Benign Prostatic Hyperplasia

An interview with Professor Andrea Tubaro (Depratment of Urology, Sant’Andrea Hospital, Sapienza University of Rome) following the ‘GreenLight™ Laser…

3 Feb 2016

Transurethral Prostate Resection for Benign Prostatic Hyperplasia

An interview with Mr Gordon Muir (Consultant Urological Surgeon, King’s College NHS Foundation Trust) following the ‘GreenLight™ Laser System for Day…

3 Feb 2016

GreenLight Laser Therapy for Benign Prostatic Hyperplasia

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress…

2 Feb 2016

Learn more about the ESMO Asia 2015 Congress

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Peter Hersey, MD, PhD…

1 Feb 2016

Delivering the promise of immunotherapy for melanoma

An interview with Professor Geert D’Haens (Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands) at the 23rd United European…

25 Jan 2016

An interview with Professor Geert D’Haens at the 23rd UEG Week

Professor Andrea Tubaro discusses the results of the GOLIATH study, which compared the Greenlight laser system with TURP in the treatment of benign…

25 Jan 2016

Results of the GOLIATH Study

Dr Ian Jackson describes the importance of day-care surgery for health service economies during the ‘GreenlightTM Laser System for Day-Case Surgery’s…

25 Jan 2016

The Importance of Day-Case Surgery

Mr Gordon Muir answers questions from the audience about the effect and impact of the Greenlight laser system for day-case surgery, which took place on…

25 Jan 2016

Q&A Session – Impact of the GreenLight Laser System for Day-Case Surgery

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Peter Van Loo, PhD, from The Francis Crick Institute, London, UK, discusses the…

20 Jan 2016

Detailed timelines of cancer development

Eileen Kaner, MSc, PhD, Hon FRCP gives an overview of a session focusing lifestyle behaviour and cancer prevention presented at the 2015 National Cancer…

20 Jan 2016

Lifestyle behaviour and cancer prevention

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Robert West, PhD, from University College London, London, UK, discusses data…

20 Jan 2016

Trends in e-cigarette use in England